Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC

Non-Small Cell Lung Carcinoma Clinical Trial

Official title:

Efficacy, Safety & Immunogenicity Study of CBT124 & EU-sourced Avastin® in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02879097
• Other study ID #: CBT124/CT/002
• Secondary ID: 2016-003301-34
• Status: Not yet recruiting
• Phase: Phase 3
• First received: August 16, 2016
• Last updated: August 22, 2016
• Start date: December 2016
• Est. completion date: May 2018

Study information

• Verified date: August 2016
• Source: Cipla BioTec Pvt. Ltd.
• Contact: Tamal Raha, PhD
• Phone: +91 7774097577
• Email: Tamal.Raha[@]Cipla.com
• Is FDA regulated: No
• Health authority: Bulgaria: Bulgarian Drug AgencyHungary: Ministry of Health, Social and Family AffairsIndia: Drugs Controller General of IndiaSouth Africa: Medical Research CouncilUkraine: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether CBT124 and Avastin® are comparable in terms of efficacy, safety, immunogenicity; and whether the pharmacokinetics of CBT124 matches that of Avastin® (pharmacokinetics is nested in this study for Indian patients).

Description:

The purpose of this study is to determine whether CBT124 and Avastin® are comparable in terms of efficacy, safety, immunogenicity; and whether the pharmacokinetics of CBT124 matches that of Avastin® (pharmacokinetics is nested in this study for Indian patients). To test the clinical equivalence in terms of efficacy and safety, a two-sided test approach based on a pre-specified range to test the null hypothesis that the proposed biosimilar is either (1) inferior to the reference product or (2) superior to the reference product based on the pre-specified equivalence margin will be used. The equivalence margins are chosen to enable detection of clinically meaningful differences in effectiveness between CBT124, candidate biosimilar bevacizumab and reference product (EU-sourced Avastin®) at the 95% confidence interval (CI). In this trial, asymmetric equivalence margins will be used, i.e., the upper (superiority) and the lower (inferiority) bounds of the equivalence margin are not symmetric. The goal is to reject the null hypothesis of non-equivalence and accept the alternative hypothesis that the two treatments (in this case, CBT124 and EU-sourced Avastin®) are equivalent (i.e., the differences between the two are not clinically and statistically meaningful). The hypothesis testing will be performed by determining if the difference in the primary end point (Objective Response Rate [ORR]) between the reference product (EUsourced Avastin®) and proposed biosimilar (CBT124) is within the equivalence margin at the 95% CI.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: May 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria: Subjects may be entered in the study only if they meet all of the following criteria:

• Adult subjects aged = 18 to 75 years (= 18 to 65 years for India) with histologically or cytologically confirmed advanced non-squamous NSCLC.

• Epidermal growth factor receptor (EGFR) negative or wild type mutations

• Stage IV (Unresectable recurrent disease or metastatic) NSCLC

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

• Evaluable disease status or measurable tumor

• Adequate hepatic, renal, and bone marrow function

• Subjects with pre-existing hypertension must be well controlled on a stable regimen of antihypertensive therapy. Have systolic blood pressure = 140 and = 90 mmHg, diastolic blood pressure = 90 and = 50 mmHg and heart rate = 40 and = 90 bpm at screening and admission.

• Ability to understand risks of participation in the study and willingness provide informed consent.

Exclusion Criteria: Subjects will not be entered in the study for any of the following reasons:

• Small cell lung cancer (SCLC) or combination of SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature

• Prior therapy with monoclonal antibodies or small molecule inhibitors against VEGF or VEGF receptors, including bevacizumab

• Prior therapy with carboplatin or paclitaxel

• Prior systemic therapy for metastatic disease. Prior systemic anticancer therapy or radiotherapy for locally-advanced NSCLC if completed < 12 months prior to screening

• Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation that in the opinion of the Investigator is likely to bleed

• Symptomatic brain metastasis

• Previous malignancy other than NSCLC in the last 5 years except for basal cell cancer of the skin or pre-invasive cancer of the cervix

• Any unresolved toxicity > Common Toxicity Criteria Grade 1 (except alopecia) from previous anticancer therapy (including radiotherapy)

• History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding. Thrombotic or hemorrhagic event = 6 months prior to screening

• History of hemoptysis greater than ½ teaspoon of bright red (fresh) blood in the past 4 weeks

• Subjects receiving long-term aspirin (> 325 mg/day), or other non-steroidal anti-inflammatory agents, or other drugs known to inhibit platelet function, treatment with dipyridamole, ticlopidine, or clopidogrel

• Subjects receiving anticoagulants

• Subjects who plan to undergo surgery during the study period

• Subjects who have undergone a major surgery, or have had a significant traumatic injury within 4 weeks prior to randomization

• Subjects who have a significant non-healing wound, or bone fracture within 4 weeks prior to randomization

• Subjects with history of gastrointestinal perforation or fistula formation

• Subjects with known hypersensitivity to any of the ingredients of the investigational products, or mammalian cell-derived products

• Female subjects who are pregnant, breast-feeding, planning to be pregnant during the study, or women of child-bearing potential (any woman who is not surgically sterile i.e., bilateral tubal ligation, total hysterectomy or < 2 years post menopause) not using a reliable method of double contraception (e.g. condom plus diaphragm, condom or diaphragm plus spermicidal gel/foam, tubal ligation, or stable dose of hormonal contraception) throughout the study period

• Male subject with a partner of childbearing potential who does not consent to the use of a reliable method of double contraception

• Subjects with uncontrolled hypertension

• Subjects with active infection assessed to be clinically significant by Investigator

• Known history of, or positive test result for human immunodeficiency virus (HIV), hepatitis C virus (test for hepatitis C virus antibody [HCVAb]) or hepatitis B virus (test for Hepatitis B surface Antigen [HBsAg])

• History of alcohol or substance abuse

• Prior treatment with any investigational drug within the 30 days prior to screening, or within 5 half-lives of the drug, whichever is longer

• Inability to comply with study requirements

• Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the subject unsuitable for enrollment.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Carcinoma

Intervention

Biological:
• CBT124
Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
• EU-sourced Avastin®
Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.

Drug:
• Carboplatin
Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
• Paclitaxel
Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cipla BioTec Pvt. Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)	Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumours (RECIST) criteria (version 1.1). Defined as the proportion of subjects whose best confirmed overall response over Week 1 to Week 19 is either Complete Response (CR) or Partial Response (PR). Confirmed best overall response (complete or partial response) may be claimed only if the criteria for each are met after a repeat radiologic tumor assessment (using RECIST criteria version 1.1) 6 weeks later.	19 weeks	Yes
Secondary	Progression-free survival (PFS) rate at 1 year	Duration of response.	1 year	Yes
Secondary	Overall Survival (OS) rate at 1 year	Duration of response.	1 year	Yes
Secondary	Pharmacokinetics: Cmax and Ctrough	Cycle 1: Cmax; Cycle 2-6: Ctrough	Cycle 6	No
Secondary	Proportion of subjects with selected adverse events (AE)	Proportion of subjects with selected adverse events (AE) of gastrointestinal perforation, hypertension, proteinuria, and pulmonary haemorrhage	1 year	Yes
Secondary	Proportion of subjects with other selected AEs	Proportion of subjects with other selected AEs of hemorrhages, wound healing complications, abscess, and fistula formation	1 year	Yes
Secondary	Proportion of subjects with other selected AEs/ SAEs/ Vital signs/Lab abnormalities	proportion of subjects with other selected AEs of Anaphylactic/ hypersensitivity/ infusion-related reactions, arterial and venous thromboembolic events, and febrile neutropenia Incidence of AEs (overall), serious adverse events (SAEs), including changes in vital signs and laboratory abnormalities	1 year	Yes
Secondary	Incidence of anti-drug (bevacizumab) antibody formation	Incidence of anti-drug (bevacizumab) antibody formation, including incidence of neutralizing antibodies; Analysis of anti-drug antibody (ADA) positive and negative sub-population for PK, safety and efficacy.	1 year	Yes
Secondary	Analysis of anti-drug antibody (ADA) positive and negative sub-population for PK, safety and efficacy	Analysis of anti-drug antibody (ADA) positive and negative sub-population for PK, safety and efficacy	1 year	Yes